Post-transplant hypertriglyceridaemia can be induced by genetic predisposition, alcohol consumption, high carbohydrate intake, diabetes, overweight and obesity, proteinuria, renal failure and IS therapy [mostly glucocorticosteroids (GCS), mammalian target of rapamycin (mTOR) and calcineurin-inhibitors (CNIs)]. The gene discussed is MTOR; the disease is hypertriglyceridemia.